1
|
Lassalle F, Marmontel O, Zawadzki C, Fretigny M, Bouvagnet P, Vinciguerra C. Recurrent F8
and F9
gene variants result from a founder effect in two large French haemophilia cohorts. Haemophilia 2018; 24:e213-e221. [DOI: 10.1111/hae.13480] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 03/06/2018] [Indexed: 12/29/2022]
Affiliation(s)
- F. Lassalle
- Centre de Biologie Pathologie; Laboratoire d'Hématologie; Centre Hospitalier Régional Universitaire de Lille; Lille France
| | - O. Marmontel
- Département de Biochimie et Biologie Moléculaire; Centre de Biologie Pathologie Est; Groupe Hospitalier Est; Hospices Civils de Lyon; Bron France
| | - C. Zawadzki
- Centre de Biologie Pathologie; Laboratoire d'Hématologie; Centre Hospitalier Régional Universitaire de Lille; Lille France
| | - M. Fretigny
- Centre de Biologie Pathologie Est; Service d'Hématologie Biologique; Groupe Hospitalier Est; Hospices Civils de Lyon; Bron France
| | - P. Bouvagnet
- Laboratoire de Cardiogénétique; Hospices Civils de Lyon; Université Lyon 1; Lyon France
| | - C. Vinciguerra
- Centre de Biologie Pathologie Est; Service d'Hématologie Biologique; Groupe Hospitalier Est; Hospices Civils de Lyon; Bron France
- Hémostase et Cancer; Université Lyon 1; Lyon France
| |
Collapse
|
2
|
Happach M, de Felipe D, Conradi H, Friedhoff VN, Schwartz E, Kleinert M, Brinker W, Zawadzki C, Keil N, Hofmann W, Schell M. On-chip free beam optics on a polymer-based photonic integration platform. Opt Express 2017; 25:27665-27670. [PMID: 29092237 DOI: 10.1364/oe.25.027665] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/07/2017] [Accepted: 10/20/2017] [Indexed: 06/07/2023]
Abstract
This paper presents on-chip free beam optics on polymer-based photonic components. Due to the circumstance that waveguide-based optics allows no direct beam access we use Gradient index (GRIN) lenses assembled into the chip to collimate the beam from the waveguides. This enables low loss power transmission over a length of 1432 µm. Even though the beam propagates through air it is possible to create a resonator with a wavelength shift of 0.002 nm/°C, hence the allowed deviations from the ITU-T grid (100 GHz) are met for ± 20 °C. In order to guarantee reliable laser stability, it is necessary to implement optical isolators at the output of the laser. This requires the insertion of bulk material into the chip and is realized by a 1050 µm thick coated glass. Due to the large gap of the free-space section, it is possible to combine different resonators together. This demonstrates the feasibility of an integrated wavelength-meter.
Collapse
|
3
|
Jourdy Y, Chatron N, Carage ML, Fretigny M, Meunier S, Zawadzki C, Gay V, Negrier C, Sanlaville D, Vinciguerra C. Study of six patients with complete F9 deletion characterized by cytogenetic microarray: role of the SOX3 gene in intellectual disability. J Thromb Haemost 2016; 14:1988-1993. [PMID: 27477789 DOI: 10.1111/jth.13430] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/16/2016] [Indexed: 11/26/2022]
Abstract
Essentials Some hemophilia B (HB) patients with complete F9 deletion present with intellectual disability (ID). We delineate six F9 complete deletions and investigate genotype/phenotype correlation. We identify SOX3 as a candidate gene for ID, acting through haploinsufficiency, in HB patients. All complete F9 deletions in ID patients should be explored with cytogenetic microarrays. SUMMARY Background Large deletions encompassing both the complete F9 gene and contiguous genes have been detected in patients with severe hemophilia B (HB). Some of these patients present other clinical features, such as intellectual disability (ID). Objectives/Methods In this study, we characterized six unrelated large deletions encompassing F9, by cytogenetic microarray analysis (CMA), to investigate genotype/phenotype correlation. Results Five of the six patients included in this study presented with ID associated with HB. CMA showed that the six large deletions, ranging in size from approximately 933 kb to 9.19 Mb, were located within the Xq26.3 to Xq28 bands. In all cases, the complete deletion of F9 was associated with the loss of various neighboring genes (5-28 other genes). The smallest region of overlap for ID was a 1.26-Mb region encompassing seven OMIM genes (LOC389895, SOX3, LINC00632, CDR1, SPANXF1, LDOC1, SPANXC). SOX3, our candidate gene for ID, encodes an early transcription factor involved in pituitary development. All of the patients studied who had both HB and ID had deletion of the SOX3 gene. Conclusions All HB patients with an atypical phenotype, especially if complete deletion of F9 is suspected, should be referred to a geneticist for possible pangenomic assessment, because haploinsufficiency of genes flanking F9, such as SOX3 in particular, may result in a broader phenotype, including ID. Such assessment would be of particular value for the genetic counseling of female carriers with F9 deletions, as it would facilitate analysis of the risk of transmitting HB associated with ID.
Collapse
Affiliation(s)
- Y Jourdy
- Hospices Civils de Lyon, Hôpital Edouard Herriot, Service d'Hématologie Biologique, Lyon, France
- EAM 4174 Hémostase, Inflammation et Sepsis, Université Claude Bernard Lyon 1, Lyon, France
| | - N Chatron
- Hospices Civils de Lyon, Groupe Hospitalier Est, Laboratoire de Cytogénétique Constitutionnelle, Bron, France
| | - M-L Carage
- Hospices Civils de Lyon, Hôpital Edouard Herriot, Service d'Hématologie Biologique, Lyon, France
| | - M Fretigny
- Hospices Civils de Lyon, Hôpital Edouard Herriot, Service d'Hématologie Biologique, Lyon, France
| | - S Meunier
- Hospices Civils de Lyon, Hôpital Cardiologique Louis Pradel, Unité d'Hémostase Clinique, Bron, France
| | - C Zawadzki
- Laboratoire d'Hématologie, CHRU de Lille, Lille, France
| | - V Gay
- Centre de Traitement de l'Hémophilie, CHG, Chambery, France
| | - C Negrier
- Hospices Civils de Lyon, Hôpital Edouard Herriot, Service d'Hématologie Biologique, Lyon, France
- EAM 4174 Hémostase, Inflammation et Sepsis, Université Claude Bernard Lyon 1, Lyon, France
- Hospices Civils de Lyon, Hôpital Cardiologique Louis Pradel, Unité d'Hémostase Clinique, Bron, France
| | - D Sanlaville
- Hospices Civils de Lyon, Groupe Hospitalier Est, Laboratoire de Cytogénétique Constitutionnelle, Bron, France
- CRN, équipe TIGER, INSERM U1028, CNRS UMR5292, Université Claude Bernard, Lyon1, France
| | - C Vinciguerra
- Hospices Civils de Lyon, Hôpital Edouard Herriot, Service d'Hématologie Biologique, Lyon, France.
- EAM 4174 Hémostase, Inflammation et Sepsis, Université Claude Bernard Lyon 1, Lyon, France.
| |
Collapse
|
4
|
Fréalle E, Gantois N, Aliouat-Denis CM, Leroy S, Zawadzki C, Perkhofer S, Aliouat EM, Dei-Cas E. Comparison of different blood compartments for the detection of circulating DNA using a rat model of Pneumocystis pneumonia. Med Mycol 2015; 53:754-9. [PMID: 26162469 DOI: 10.1093/mmy/myv050] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/26/2015] [Accepted: 05/31/2015] [Indexed: 12/28/2022] Open
Abstract
Pneumocystis is mostly found in the alveolar spaces, but circulation of viable organisms also occurs and suggests that the detection of DNA in blood could be used as a noninvasive procedure to improve the diagnosis of Pneumocystis pneumonia (PcP). In order to determine the optimal compartment for Pneumocystis DNA detection, we used a rat model of PcP and tested the presence of Pneumocystis with a quantitative mtLSU targeting real-time PCR in four blood compartments: whole blood, clot, serum and Platelet-Rich-Plasma (PRP). All samples from 4 Pneumocystis-free control rats were negative. Pneumocystis was detected in 79, 64, 57, and 57% of samples from 14 PcP rats, respectively, but DNA release was not related to pulmonary loads. These data confirm the potential usefulness of Pneumocystis DNA detection in the blood for PcP diagnosis and suggest that whole blood could be the most appropriate compartment for Pneumocystis detection.
Collapse
Affiliation(s)
- E Fréalle
- Centre d'Infection et d'Immunité de Lille (CIIL), Inserm U1019 - CNRS UMR 8204 - Université de Lille, IFR142, Institut Pasteur de Lille, France Laboratoire de Parasitologie-Mycologie, CHRU de Lille & Faculté de Médecine de Lille - Université de Lille, France
| | - N Gantois
- Centre d'Infection et d'Immunité de Lille (CIIL), Inserm U1019 - CNRS UMR 8204 - Université de Lille, IFR142, Institut Pasteur de Lille, France
| | - C M Aliouat-Denis
- Centre d'Infection et d'Immunité de Lille (CIIL), Inserm U1019 - CNRS UMR 8204 - Université de Lille, IFR142, Institut Pasteur de Lille, France Laboratoire de Parasitologie, Faculté de Pharmacie de Lille - Université de Lille, France
| | - S Leroy
- Laboratoire de Parasitologie-Mycologie, CHRU de Lille & Faculté de Médecine de Lille - Université de Lille, France
| | - C Zawadzki
- Laboratoire d'Hématologie & EA2693 Interface sang - vaisseaux et réparation cardiovasculaire, CHRU de Lille & Faculté de Médecine de Lille - Université de Lille, France
| | - S Perkhofer
- University of Applied Sciences Tyrol, Innsbruck, Austria
| | - E M Aliouat
- Centre d'Infection et d'Immunité de Lille (CIIL), Inserm U1019 - CNRS UMR 8204 - Université de Lille, IFR142, Institut Pasteur de Lille, France Laboratoire de Parasitologie, Faculté de Pharmacie de Lille - Université de Lille, France
| | - E Dei-Cas
- Centre d'Infection et d'Immunité de Lille (CIIL), Inserm U1019 - CNRS UMR 8204 - Université de Lille, IFR142, Institut Pasteur de Lille, France Laboratoire de Parasitologie-Mycologie, CHRU de Lille & Faculté de Médecine de Lille - Université de Lille, France
| |
Collapse
|
5
|
De Paoli F, Eeckhoute J, Copin C, Vanhoutte J, Duhem C, Derudas B, Dubois-Chevalier J, Colin S, Zawadzki C, Jude B, Haulon S, Lefebvre P, Staels B, Chinetti-Gbaguidi G. The neuron-derived orphan receptor 1 (NOR1) is induced upon human alternative macrophage polarization and stimulates the expression of markers of the M2 phenotype. Atherosclerosis 2015; 241:18-26. [PMID: 25941992 DOI: 10.1016/j.atherosclerosis.2015.04.798] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/17/2014] [Revised: 04/08/2015] [Accepted: 04/22/2015] [Indexed: 11/28/2022]
Abstract
BACKGROUND Atherosclerosis is an inflammatory disease in which macrophages play a crucial role. Macrophages are present in different phenotypes, with at the extremes of the spectrum the classical M1 pro-inflammatory and the alternative M2 anti-inflammatory macrophages. The neuron-derived orphan receptor 1 (NOR1), together with Nur77 and Nurr1, are members of the NR4A orphan nuclear receptor family, expressed in human atherosclerotic lesion macrophages. However, the role of NOR1 in human macrophages has not been studied yet. OBJECTIVES To determine the expression and the functions of NOR1 in human alternative macrophages. METHODS AND RESULTS In vitro IL-4 polarization of primary monocytes into alternative M2 macrophages enhances NOR1 expression in human but not in mouse macrophages. Moreover, NOR1 expression is most abundant in CD68+MR+ alternative macrophage-enriched areas of human atherosclerotic plaques in vivo. Silencing NOR1 in human alternative macrophages decreases the expression of several M2 markers such as the Mannose Receptor (MR), Interleukin-1 Receptor antagonist (IL-1Ra), CD200 Receptor (CD200R), coagulation factor XIII A1 polypeptide (F13A1), Interleukin 10 (IL-10) and the Peroxisome Proliferator-Activated Receptor (PPAR)γ. Bioinformatical analysis identified F13A1, IL-1Ra, IL-10 and the Matrix Metalloproteinase-9 (MMP9) as potential target genes of NOR1 in human alternative macrophages. Moreover, expression and enzymatic activity of MMP9 are induced by silencing and repressed by NOR1 overexpression in M2 macrophages. CONCLUSIONS These data identify NOR1 as a transcription factor induced during alternative differentiation of human macrophages and demonstrate that NOR1 modifies the alternative macrophage phenotype.
Collapse
Affiliation(s)
- F De Paoli
- Université Lille 2, F-59000 Lille, France; Inserm, U1011, F-59000 Lille, France; Institut Pasteur de Lille, F-59019 Lille, France; European Genomic Institute for Diabetes (EGID), FR 3508, F-59000 Lille, France
| | - J Eeckhoute
- Université Lille 2, F-59000 Lille, France; Inserm, U1011, F-59000 Lille, France; Institut Pasteur de Lille, F-59019 Lille, France; European Genomic Institute for Diabetes (EGID), FR 3508, F-59000 Lille, France
| | - C Copin
- Université Lille 2, F-59000 Lille, France; Inserm, U1011, F-59000 Lille, France; Institut Pasteur de Lille, F-59019 Lille, France; European Genomic Institute for Diabetes (EGID), FR 3508, F-59000 Lille, France
| | - J Vanhoutte
- Université Lille 2, F-59000 Lille, France; Inserm, U1011, F-59000 Lille, France; Institut Pasteur de Lille, F-59019 Lille, France; European Genomic Institute for Diabetes (EGID), FR 3508, F-59000 Lille, France
| | - C Duhem
- Université Lille 2, F-59000 Lille, France; Inserm, U1011, F-59000 Lille, France; Institut Pasteur de Lille, F-59019 Lille, France; European Genomic Institute for Diabetes (EGID), FR 3508, F-59000 Lille, France
| | - B Derudas
- Université Lille 2, F-59000 Lille, France; Inserm, U1011, F-59000 Lille, France; Institut Pasteur de Lille, F-59019 Lille, France; European Genomic Institute for Diabetes (EGID), FR 3508, F-59000 Lille, France
| | - J Dubois-Chevalier
- Université Lille 2, F-59000 Lille, France; Inserm, U1011, F-59000 Lille, France; Institut Pasteur de Lille, F-59019 Lille, France; European Genomic Institute for Diabetes (EGID), FR 3508, F-59000 Lille, France
| | - S Colin
- Université Lille 2, F-59000 Lille, France; Inserm, U1011, F-59000 Lille, France; Institut Pasteur de Lille, F-59019 Lille, France; European Genomic Institute for Diabetes (EGID), FR 3508, F-59000 Lille, France
| | - C Zawadzki
- Université Lille 2, F-59000 Lille, France; Centre Hospitalier Régional Universitaire de Lille, France
| | - B Jude
- Université Lille 2, F-59000 Lille, France; Centre Hospitalier Régional Universitaire de Lille, France
| | - S Haulon
- Centre Hospitalier Régional Universitaire de Lille, France
| | - P Lefebvre
- Université Lille 2, F-59000 Lille, France; Inserm, U1011, F-59000 Lille, France; Institut Pasteur de Lille, F-59019 Lille, France; European Genomic Institute for Diabetes (EGID), FR 3508, F-59000 Lille, France
| | - B Staels
- Université Lille 2, F-59000 Lille, France; Inserm, U1011, F-59000 Lille, France; Institut Pasteur de Lille, F-59019 Lille, France; European Genomic Institute for Diabetes (EGID), FR 3508, F-59000 Lille, France.
| | - G Chinetti-Gbaguidi
- Université Lille 2, F-59000 Lille, France; Inserm, U1011, F-59000 Lille, France; Institut Pasteur de Lille, F-59019 Lille, France; European Genomic Institute for Diabetes (EGID), FR 3508, F-59000 Lille, France; INSERM, U 1081, Institute for Research on Cancer and Aging of Nice (IRCAN), "Aging and Diabetes" team, France; University of Nice-Sophia Antipolis, Nice, France; Clinical Chemistry Laboratory, University Hospital, Nice, France
| |
Collapse
|
6
|
Chinetti-Gbaguidi G, Copin C, Derudas B, Vanhoutte J, Zawadzki C, Jude B, Haulon S, Pattou F, Marx N, Staels B. The coronary artery disease-associated gene C6ORF105 is expressed in human macrophages under the transcriptional control of PPARγ. FEBS Lett 2015; 589:461-6. [PMID: 25595457 DOI: 10.1016/j.febslet.2015.01.002] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/28/2014] [Revised: 12/17/2014] [Accepted: 01/02/2015] [Indexed: 11/27/2022]
Abstract
Coronary artery disease (CAD) is a major cause of morbidity and mortality. Mutations in C6ORF105, associated with decreased gene expression, positively correlate with the risk of CAD in Chinese populations. Moreover, the C6ORF105-encoded protein may play a role in coagulation. Here, we report that C6ORF105 gene expression is lower in circulating mononuclear cells from obese diabetic than lean subjects. Moreover, C6ORF105 is expressed in human macrophages and atherosclerotic lesions, where its expression positively correlates with expression of the transcription factor Peroxisome Proliferator-Activated Receptor (PPAR)γ. Activation of PPARγ increases, in a PPARγ-dependent manner, the expression of C6ORF105 in human macrophages and atherosclerotic lesions.
Collapse
Affiliation(s)
- G Chinetti-Gbaguidi
- Université Lille 2, F-59000 Lille, France; Inserm, U1011, F-59000 Lille, France; Institut Pasteur de Lille, F-59019 Lille, France; European Genomic Institute for Diabetes (EGID), FR 3508, F-59000 Lille, France
| | - C Copin
- Université Lille 2, F-59000 Lille, France; Inserm, U1011, F-59000 Lille, France; Institut Pasteur de Lille, F-59019 Lille, France; European Genomic Institute for Diabetes (EGID), FR 3508, F-59000 Lille, France
| | - B Derudas
- Université Lille 2, F-59000 Lille, France; Inserm, U1011, F-59000 Lille, France; Institut Pasteur de Lille, F-59019 Lille, France; European Genomic Institute for Diabetes (EGID), FR 3508, F-59000 Lille, France
| | - J Vanhoutte
- Université Lille 2, F-59000 Lille, France; Inserm, U1011, F-59000 Lille, France; Institut Pasteur de Lille, F-59019 Lille, France; European Genomic Institute for Diabetes (EGID), FR 3508, F-59000 Lille, France
| | - C Zawadzki
- Université Lille 2, F-59000 Lille, France; Centre Hospitalier Régional Universitaire de Lille, France
| | - B Jude
- Université Lille 2, F-59000 Lille, France; Centre Hospitalier Régional Universitaire de Lille, France
| | - S Haulon
- Centre Hospitalier Régional Universitaire de Lille, France
| | - F Pattou
- Université Lille 2, F-59000 Lille, France; European Genomic Institute for Diabetes (EGID), FR 3508, F-59000 Lille, France; Centre Hospitalier Régional Universitaire de Lille, France; Department of Endocrine Surgery, University Hospital, F-59000 Lille, France
| | - N Marx
- Department of Internal Medicine I, University Hospital Aachen, D-52074 Aachen, Germany
| | - B Staels
- Université Lille 2, F-59000 Lille, France; Inserm, U1011, F-59000 Lille, France; Institut Pasteur de Lille, F-59019 Lille, France; European Genomic Institute for Diabetes (EGID), FR 3508, F-59000 Lille, France.
| |
Collapse
|
7
|
Mourey G, Tachon G, Pellequer JL, Zawadzki C, Trossaërt M, Bertrand MA, Schved JF, Giansily-Blaizot M. A Haut-Doubs FVII variant depending on species-derived-thromboplastin reagent (F7:p.Arg337His). Haemophilia 2014; 20:e347-9. [DOI: 10.1111/hae.12455] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 03/26/2014] [Indexed: 11/27/2022]
Affiliation(s)
- G. Mourey
- Laboratoire d'hémostase; Etablissement Français du Sang; Besançon France
| | - G. Tachon
- Département d'hématologie biologique; CHU de Montpellier; Hôpital Saint Eloi; Montpellier France
| | - J.-L. Pellequer
- CEA, iBEB; Service de Biochimie et Toxicologie Nucléaire; Bagnols sur Cèze France
| | - C. Zawadzki
- Laboratoire d'Hématologie; Centre de Biologie et Pathologie EA-2693; Centre Hospitalier Régional et Universitaire; Lille France
| | - M. Trossaërt
- Centre Régional de Traitement de l'Hémophilie; Laboratoire hématologie; CHU Hôtel-Dieu; Nantes France
| | - M.-A. Bertrand
- Centre Régional de Traitement de l'Hémophilie; Service d'hématologie CHU Besançon; Besançon France
| | - J.-F. Schved
- Département d'hématologie biologique; CHU de Montpellier; Hôpital Saint Eloi; Montpellier France
| | - M. Giansily-Blaizot
- Département d'hématologie biologique; CHU de Montpellier; Hôpital Saint Eloi; Montpellier France
| |
Collapse
|
8
|
Elkalioubie A, Arbesu Y Miar A, Corseaux D, Dupont A, Zawadzki C, Juthier F, Smadja D, Chinetti G, Van Belle E, Susen S. Profibrotic commitment of aortic valve interstitial cell via tissue factor expression and signalling. Eur Heart J 2013. [DOI: 10.1093/eurheartj/eht309.p3907] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
9
|
Wurtz A, Hysi I, Zawadzki C, Copin MC. Reply to Martinod. Eur J Cardiothorac Surg 2012. [DOI: 10.1093/ejcts/ezr257] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
10
|
Zawadzki C, Chatelain N, Delestre M, Susen S, Quesnel B, Breyne J, Juthier F, Vincentelli A, Jeanpierre E, Azzaoui R, Haulon S, Corseaux D, Torpier G, Staels B, Van Belle E, Jude B. A004 L’hyperméthylation du gène du tissue factor pathway inhibitor-2 est associée à une diminution de son expression dans la plaque d’athérosclérose carotidienne. Arch Cardiovasc Dis 2009. [DOI: 10.1016/s1875-2136(09)72137-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
11
|
Jude B, Zawadzki C, Susen S, Corseaux D. Relevance of tissue factor in cardiovascular disease. Arch Mal Coeur Vaiss 2005; 98:667-71. [PMID: 16007822] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/03/2023]
Abstract
Overexpression and exposition of tissue factor (TF) in atherosclerotic plaques and/or arterial thrombi are critical events in atherothrombosis. TF, the receptor for factor VII (FVII) and activated factor VII (FVIIa), is the principal initiator of blood coagulation and induces thrombin generation leading to fibrin formation and platelet activation. TF also plays a major role in cell migration and angiogenesis. TF activity is downregulated by Tissue Factor Pathway Inhibitor (TFPI), a Kunitz-type inhibitor, which forms a neutralizing complex with TF, FVIIa and activated factor X. In physiological conditions, TF is absent from vascular cells which come into contact with flowing blood and is present as an inactive pool in fibroblasts and smooth muscle cells (SMC). In contrast, TF is widely expressed in atherosclerotic plaques and is found in macrophages, SMCs, and foam-cells and also in extracellular matrix and acellular lipid-rich core. TF expression is up-regulated by inflammatory cytokines and oxidized lipids. Plaque thrombogenicity is directly correlated to their TF content. After fibrous cap disruption, TF is exposed on plaque surface and triggers thrombus formation leading to arterial lumen occlusion and/or downstream embolization. In coronary and carotid plaques, TF content was found to be higher in plaques from symptomatic than asymptomatic patients. Soluble forms of TF and microparticles of monocyte and platelet origin, and bearing TF, constitute "blood-born TF". The contribution of this TF pool to arterial thrombosis is still under discussion. TF pathway is a target for new therapeutic agents that can decrease TF activity, such as active site-inactivated factor VIIa, recombinant TFPI and antibodies against TF or peptides interfering with TF-FVIIa complex activity.
Collapse
Affiliation(s)
- B Jude
- INSERM-ERI-9, université de Lille 2, EA 2693, centre hospitalier régional universitaire, Institut d'hématologie, Lille.
| | | | | | | |
Collapse
|
12
|
Susen S, Sautiere K, Zawadzki C, Bauters A, Dallongeville J, Asseman P, Bauters C, Lablanche JM, Jude B, Van Belle E. Tissue factor predicts long-term outcome after percutaneous coronary revascularization. J Thromb Haemost 2003. [DOI: 10.1111/j.1538-7836.2003.tb04453.x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
13
|
Neve BP, Corseaux D, Chinetti G, Zawadzki C, Fruchart JC, Duriez P, Staels B, Jude B. PPARalpha agonists inhibit tissue factor expression in human monocytes and macrophages. Circulation 2001; 103:207-12. [PMID: 11208678 DOI: 10.1161/01.cir.103.2.207] [Citation(s) in RCA: 136] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Abstract
BACKGROUND Monocytic tissue factor (TF) expression may contribute to thrombogenicity associated with plaque rupture and may propagate thrombus formation at the site of vascular lesions. Induction of monocytic TF expression by endotoxin is mediated by the activation of transcription factors such as AP-1 and NF-kappaB. Both these signaling pathways are modulated by peroxisome proliferator-activated receptor-alpha (PPARalpha). Therefore, we have studied the effects of fibrates and other PPARalpha agonists on the expression of TF. METHODS AND RESULTS We show that PPARalpha protein, like primary human monocytes, is also expressed in the human monocytic THP-1 cell line. Fenofibric acid, WY14643, and GW2331 inhibited TF mRNA upregulation after stimulation of THP-1 cells with lipopolysaccharide or interleukin-1ss. In primary human monocytes and macrophages, the lipopolysaccharide- or interleukin-1ss-mediated induction of TF activity was also inhibited by fenofibric acid, WY14643, or GW2331. CONCLUSIONS These data indicate that activation of PPARalpha results in the downregulation of the TF gene. Our results suggest a novel role for PPARalpha in the control of atherosclerotic plaque thrombogenicity through its effects on TF expression in monocytes and macrophages.
Collapse
Affiliation(s)
- B P Neve
- Département d'Athérosclérose, U.325 INSERM, Institut Pasteur de Lille, and the Faculté de Pharmacie, Université de Lille II, France
| | | | | | | | | | | | | | | |
Collapse
|
14
|
Michon-Pasturel U, Susen S, Zawadzki C, Bauters A, Trillot N, Jude B. L'hypercoagulabilité des femmes sous pilule œstroprogestative peut être liée à une augmentation du facteur tissulaire ? Rev Med Interne 2000. [DOI: 10.1016/s0248-8663(00)90088-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
15
|
Susen S, Hazzan M, Labalette M, Zawadzki C, Dessaint JP, Lelièvre G, Jude B, Noël C. Pentoxifylline prevents upregulation of monocyte tissue factor in renal transplant recipients undergoing post-graft complications. Thromb Haemost 2000; 84:764-9. [PMID: 11127852] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/18/2023]
Abstract
Pentoxifylline (PTX) has been demonstrated to improve graft survival in renal transplant recipients undergoing post graft complications. As activated monocytes are possible initiators of vascular damage through tissue factor (TF) expression, we evaluated the monocyte TF expression and endothelium activation markers in 140 consecutive patients receiving cadaveric kidney grafts, randomized in a double-blind study comparing PTX versus placebo. Monocyte TF expression and plasma von Willebrand factor, tissue plasminogen activator, thrombomodulin and tumor necrosis factor-alpha (TNF-alpha) levels were determined before transplantation and each month after. Additional samplings were realized in case of acute rejection. TF and TNF-alpha expression were significantly modified after graft. In patients with complications, PTX prevented the increase of TF expression at month one, and after rejection episodes. Endothelium activation markers were significantly modified after graft and in patients with complications but PTX had no significant effect on their plasma levels. These results suggest that the protective effect of PTX on graft survival could be related to the prevention of monocyte TF upregulation associated with complications.
Collapse
Affiliation(s)
- S Susen
- Laboratoire d'Hématologie, Centre Hospitalier Regional Universitaire, Lille, France
| | | | | | | | | | | | | | | |
Collapse
|
16
|
Trillot N, Zawadzki C, Watel A, Jude B. [G20210A transition in the prothrombin gene and venous thromboembolic disease]. Rev Med Interne 2000; 21:911-4. [PMID: 11075405 DOI: 10.1016/s0248-8663(00)00247-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
INTRODUCTION Genetic predisposition to venous thrombosis can be due to coagulation inhibitor deficiencies (antithrombin, protein C or protein S) or to activated protein C resistance resulting from factor V Leiden mutation (FV Leiden). Poort et al. recently identified a new polymorphism in the 3'-untranslated region of the prothrombin gene, the G20210A transition (FII G20210A), which was found to be associated with an increased risk of venous thrombosis. EXEGESIS The prevalence of the A allele is approximately 1 to 4% in the general population, and 5 to 7% in patients with venous thrombosis. Heterozygous carriers have a three to five times increased risk of thrombosis. The diagnosis is based on a polymerase chain reaction technique and restriction enzyme digestion from genomic DNA. Recent studies aim to determine the relative risk of thrombosis and the clinical features which are associated with the mutation (age of first thrombosis, recurrence). The thrombotic risk seems to be higher when FII G20210A transition is associated with the FV Leiden mutation. CONCLUSION The presence of heterozygous FII G20210A transition does not modify the management of acute thrombotic events but can lead to an increase in the duration of the anticoagulant treatment. When such a genetic abnormality is identified, thorough information of the patient is needed, including on the prophylactic heparin in high-risk situations and caution on the prescription of oral contraceptives containing estrogens.
Collapse
Affiliation(s)
- N Trillot
- Laboratoire d'hémostase, hôpital Cardiologique, CHRU, Lille, France
| | | | | | | |
Collapse
|
17
|
Zawadzki C, Gaveriaux V, Trillot N, Bauters A, Watel A, Alhenc-Gelas M, Preudhomme C, Jude B. Homozygous G20210A transition in the prothrombin gene associated with severe venous thrombotic disease: two cases in a French family. Thromb Haemost 1998; 80:1027-8. [PMID: 9869179] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/09/2023]
|
18
|
Bauters A, Zawadzki C, Bura A, Théry C, Watel A, Subtil D, Aiach M, Emmerich J, Jude B. Homozygous variant of antithrombin with lack of affinity for heparin: management of severe thrombotic complications associated with intrauterine fetal demise. Blood Coagul Fibrinolysis 1996; 7:705-10. [PMID: 8958394 DOI: 10.1097/00001721-199610000-00008] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
Patients with homozygous heparin-binding-site (HBS) qualitative antithrombin deficiencies are at significant risk of venous and arterial thrombosis. We report on the eighth case of homozygous HBS deficiency, and the fourth case concerning the Arg 47-Cys mutation. The proposita is a 25 year old, without known thrombotic antecedent, despite an oral contraceptive therapy for 7 years. After 25 weeks of a first pregnancy, she presented an intrauterine fetal demise complicated with deep vein thrombosis and pulmonary embolism. Heparin therapy was inefficient (no clinical nor angiographic improvement, no biological hypocoagulability). Heparin cofactor activity was < 10%, antigen concentration was normal. The crossed immunoelectrophoresis of patient's plasma, with and without heparin, showed a typical profile of qualitative HBS antithrombin deficiency. The molecular analysis revealed an homozygous Arg 4-Cys mutation. Antithrombotic therapy was achieved with continuous infusion of antithrombin concentrates (80 IU/kg/day) and unfractionated heparin (500 IU/kg/day) during 12 days, leading to clinical improvement, and followed by treatment with vitamin K antagonists. This observation emphasizes the risk of intrauterine fetal demise and the inefficiency of heparin therapy without antithrombin infusion in type II HBS homozygous deficiency. The management of a future pregnancy will probably require repeated infusions of antithrombin.
Collapse
Affiliation(s)
- A Bauters
- Laboratoire d'Hematologie A, Hôpital Cardiologique, Lille, France
| | | | | | | | | | | | | | | | | |
Collapse
|